Review: taking Celebrex and Methylprednisolone together


Summary

Drug interactions are reported among people who take Celebrex and Methylprednisolone together. This review analyzes the effectiveness and drug interactions between Celebrex and Methylprednisolone. It is created by eHealthMe based on reports of 927 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Celebrex and Methylprednisolone >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Celebrex

Celebrex has active ingredients of celecoxib. It is often used in arthritis. (latest outcomes from Celebrex 83,109 users)

Methylprednisolone

Methylprednisolone has active ingredients of methylprednisolone. It is often used in rheumatoid arthritis. (latest outcomes from Methylprednisolone 22,611 users)

On Aug, 28, 2016

927 people who take Celebrex, Methylprednisolone are studied.


Number of reports submitted per year:

Celebrex and Methylprednisolone drug interactions.

Drug effectiveness over time:

Celebrex:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Methylprednisolone:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Celebrex:
  • female: 0.0% - (0 of 2 people)
  • male: 0.0% - (0 of 0 people)
Methylprednisolone:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Celebrex:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Methylprednisolone:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • blood alkaline phosphatase increased
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • asthma
  • diarrhoea
  • blood lactate dehydrogenase increased
  • dermatitis contact
  • gamma-glutamyltransferase increased
  • influenza
  • vomiting
1 - 6 months:
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • asthma
  • blood alkaline phosphatase increased
  • blood lactate dehydrogenase increased
  • dermatitis contact
  • diarrhoea
  • gamma-glutamyltransferase increased
  • influenza
  • abscess limb
6 - 12 months:
  • sudden death
  • coronary artery disease
  • nausea
  • back pain
  • drug ineffective
  • hypersomnia
  • vomiting
  • weight decreased
  • abdominal pain
  • acute sinusitis
1 - 2 years:
  • pneumocystis jiroveci pneumonia
  • cardiac arrest
  • blood pressure increased
  • circulatory collapse
  • haematemesis
  • international normalised ratio increased
  • oesophageal ulcer haemorrhage
  • pain
  • respiratory arrest
  • acute myocardial infarction
2 - 5 years:
  • sudden death
  • thrombosis
  • cardiac failure congestive
  • dyspnoea
  • heart rate increased
  • intestinal ischaemia
  • mitral valve incompetence
  • myalgia
  • orthopnoea
  • panniculitis
5 - 10 years:
  • deep vein thrombosis
  • intestinal ischaemia
  • panniculitis
  • pulmonary embolism
  • thrombosis
  • abdominal pain
  • pneumocystis jiroveci pneumonia
  • sudden death
  • cardiac failure congestive
  • cardiovascular disorder
10+ years:
  • periarthritis
  • blister
  • joint injury
  • joint swelling
  • metamorphopsia
  • vision blurred
not specified:
  • pain
  • anxiety
  • back pain
  • dyspnoea
  • arthralgia
  • nausea
  • fatigue
  • osteonecrosis of jaw
  • pain in extremity
  • bronchitis

Most common drug interactions by gender *:

female:
  • pain
  • anxiety
  • arthralgia
  • nausea
  • back pain
  • fatigue
  • dyspnoea
  • bronchitis
  • osteonecrosis of jaw
  • pain in extremity
male:
  • anxiety
  • pain
  • dyspnoea
  • diarrhoea
  • drug ineffective
  • back pain
  • asthenia
  • injury
  • arthralgia
  • fall

Most common drug interactions by age *:

0-1:
  • activities of daily living impaired
  • anhedonia
  • anxiety
  • balance disorder
  • bronchitis
  • extrapyramidal disorder
  • injury
  • muscle spasms
  • myoclonus
  • neuropathy peripheral
10-19:
  • pain
  • pulmonary embolism
  • anxiety
  • blood prolactin increased
  • depression
  • electrocardiogram qt prolonged
  • femur fracture
  • lethargy
  • musculoskeletal stiffness
  • suicidal ideation
20-29:
  • drug withdrawal syndrome
  • anxiety
  • constipation
  • depression
  • nausea
  • dyspnoea
  • laryngeal oedema
  • pharyngeal oedema
  • drug dependence
  • dysmenorrhoea
30-39:
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • gamma-glutamyltransferase increased
  • asthma
  • blood alkaline phosphatase increased
  • blood lactate dehydrogenase increased
  • dermatitis contact
  • diarrhoea
  • influenza
  • anxiety
40-49:
  • drug ineffective
  • depression
  • insomnia
  • anxiety
  • back pain
  • fall
  • dyspnoea
  • arthralgia
  • pain
  • dizziness
50-59:
  • pain
  • arthralgia
  • fatigue
  • anxiety
  • osteonecrosis of jaw
  • emotional distress
  • nausea
  • metastases to bone
  • pain in extremity
  • osteoarthritis
60+:
  • anxiety
  • pain
  • osteonecrosis of jaw
  • back pain
  • bronchitis
  • dyspnoea
  • osteoarthritis
  • arthralgia
  • intervertebral disc protrusion
  • pain in extremity

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Celebrex and Methylprednisolone?

Can you answer these questions?

More questions for: Celebrex, Methylprednisolone

You may be interested in these reviews

More reviews for: Celebrex, Methylprednisolone

On eHealthMe, Celebrex (celecoxib) is often used to treat arthritis. Methylprednisolone (methylprednisolone) is often used to treat rheumatoid arthritis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.